Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H32N2O4 |
| Molecular Weight | 399.5119 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
| Stereo Comments | Cis/trans ring substitution |
SHOW SMILES / InChI
SMILES
CN(CCN1CCCCC1)C(=O)[C@H]2CC[C@@]3(CC2)OC(=O)C4=C3C=CC(O[11CH3])=C4
InChI
InChIKey=AEWLECDUIOHVBW-YVGPUXTASA-N
InChI=1S/C23H32N2O4/c1-24(14-15-25-12-4-3-5-13-25)21(26)17-8-10-23(11-9-17)20-7-6-18(28-2)16-19(20)22(27)29-23/h6-7,16-17H,3-5,8-15H2,1-2H3/t17-,23-/i2-1
| Molecular Formula | C23H32N2O4 |
| Molecular Weight | 399.5119 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 17:18:02 GMT 2025
by
admin
on
Tue Apr 01 17:18:02 GMT 2025
|
| Record UNII |
IO4B35679F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
IO4B35679F
Created by
admin on Tue Apr 01 17:18:02 GMT 2025 , Edited by admin on Tue Apr 01 17:18:02 GMT 2025
|
PRIMARY | |||
|
1246765-07-0
Created by
admin on Tue Apr 01 17:18:02 GMT 2025 , Edited by admin on Tue Apr 01 17:18:02 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET->INVERSE AGONIST |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
RESULTS: The mean effective dose for (11)C-MK-8278 was 5.4 +/- 1.1 .MU.Sv/MBq. Human brain kinetics showed rapid high uptake and fast washout. Binding potential values can be assessed using the pons as a reference region, with a test-retest repeatability of 7%. Drug RO data showed low interindividual variability per dose (mean RO SD, 2.1%), and a targeted 90% RO can be reached for both IAs at clinically feasible doses.
CONCLUSION: (11)C-MK-8278 is a useful novel PET radioligand for determination of human cerebral H3 receptor binding and allows highly reproducible in vivo brain occupancy of H3-targeting drugs, hereby enabling the evaluation of novel compounds in early development to select doses and schedules.
|